- Quotes
- Dashboard
- Chart
- Historical Prices
- Options
- News & PR
- News
- Market Currents
- Press Releases
- Coverage
- Cramer
- Top Analysts
- Business Intelligence
- Transcripts
- Events
- Key Developments
- Earnings
- History & Projected
- Consensus
- Peer Earnings
- Filings
- SEC Filings
- Annual Report
- Financials
- Income Statement
- Balance Sheet
- Cash Flow
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
AMGN Market Currents
more »
-
May 17 GSK, J&J (JNJ) and Amgen (AMGN) yesterday released positive results from small trials of cancer drugs ahead of a big industry meeting in early June. GSK combined two melanoma medicines, JNJ's already approve Zytiga helped eliminate prostate cancer that hadn't yet spread, and Amgen has revived the once discarded rilotumumab for treating gastric cancer.
Comment![Healthcare]
AMGN in Focus
more »
AMGN Related Articles
more »
AMGN News
more »
-
at MarketWatch.com (Tue, 12:01AM)
-
at MarketWatch.com (Mon, 11:01AM)
-
at MarketWatch.com (Apr 26, 2012)
-
at CNBC.com (Apr 25, 2012)
-
at CNBC.com (Apr 24, 2012)
AMGN Press Releases and Filings
more »
-
PR Newswire (Wed, 5:05PM)
-
PR Newswire (May 16, 2012)
-
PR Newswire (May 16, 2012)
-
PR Newswire (May 11, 2012)
-
PR Newswire (May 9, 2012)
AMGN Latest Transcript
more »
AMGN Cramer
more »
-
Tue, Jan 10
-
Tue, Nov 22, 2011
-
Sun, Jan 17, 2010
AMGN Instablog posts
more »
AMGN vs. ETF Alternatives
Company Description
Amgen Inc. (including its subsidiaries, referred to as “Amgen,” “the Company,” “we,” “our” and “us”) is the world’s largest independent biotechnology medicines company. We discover, develop, manufacture and market medicines for grievous illnesses. We focus solely on human therapeutics and... More
